Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature

Mohamed Belmouhand 1,2*, Christina Eckmann-Hansen 1,2, Tomas Ilginis 1, Eva Birgitte Leinøe 3, Bo Kok Mortensen 4 and Michael Larsen 1,2

Abstract

Background: Deferoxamine retinopathy is the informally designated term used to describe a characteristic pattern of outer retinal degeneration in iron-overloaded chronic anemia patients who are treated with deferoxamine. We hypothesize that insufficiently treated iron overloading and not only deferoxamine is the cause of the retinal degeneration. Our case report is based on exposure histories of two anemia patients and literature review.

Case presentation: Both anemia patients presented with bilateral visual loss secondary to photoreceptor and retinal pigment epithelium degeneration. Chart review showed that visual loss came after a year-long slow, and rather monotonous rise in plasma ferritin concentrations, with no obvious relation to iron chelator exposure. In one patient, the onset of symptomatic visual loss came after a bout of fever followed by two additional febrile episodes, all accompanied by plasma ferritin spikes. Adjustment of iron chelation therapy did not improve visual function. Experimental studies clearly show that both systemic and intraocular exposure to iron ions can induce retinal degeneration.

Conclusion: The available evidence indicates that retinal degeneration in chronic anemia patients treated by deferoxamine is cause by insufficient iron chelation, not by deferoxamine. The actual role of iron chelating agents may be to promote a long enough survival to allow the slow development of retinal siderosis.

Keywords: Anemia, Iron chelation, Iron overload, Deferoxamine, Retinopathy, Case report

Introduction

The iron content of the human body is regulated at the level of intestinal absorption. There is no regulated form of excretion in individuals with excessive iron store. This can lead to iron toxicity in patients with a chronic need for blood transfusions. If untreated, many patients with hematological disease will therefore die from heart and liver failure within 10 years [1]. To avoid fatal cardiac complications of hemosiderosis (systemic iron overload), individuals with chronic transfusion-treated anemia are therefore treated with an iron chelating agent.

The introduction of the iron chelating agent deferoxamine in 1968 was followed by a marked reduction in mortality from hemosiderosis. Subsequently, the term deferoxamine retinopathy was coined for a characteristic pigmented degeneration of the outer retina with annular visual defects and night blindness that was seen among
chronic anemia patients treated with an iron chelating agent (e.g., deferoxamine) [2, 3]. Several studies, primarily case-reports, have suggested that iron chelators may cause retinopathy [3–7]. However, other studies have presented results that contradict this notion [8, 9], and the demonstration of a potential role of trace element imbalance in optic nerve degeneration further complicates the evaluation of visual loss in patients suffering from chronic anemia [10]. Finally, the potential role of iron in inducing retinal degeneration has received little attention in the context of chronic anemia management.

Human retinal pigment epithelium (RPE) cells contain transferrin receptors that enable endocytosis-mediated iron uptake from the choroid, and iron is known to be toxic to the retina, especially the RPE [11, 12]. The degenerative damage is believed to originate from iron-induced oxidative stress [12]. We therefore hypothesize that prolonged hemosiderosis plays a major role in the development of retinopathy in transfusion-dependent anemia patients, alone or in combination with iron chelating agents.

The aim of the study was to examine iron levels and deferoxamine treatment in two patients with chronic anemia before, during and after vision loss to more accurately determine the role of hemosiderosis in what is commonly called deferoxamine retinopathy. We have reviewed the evidence base of this nosological entity in the light of data from two patients with chronic anemia who consented to having their data published.

**Case presentation**

**Patient 1**

A 72-year-old man presented with blurred vision in both eyes beginning 1 week earlier as a dark, partially transparent area in the center of both visual fields. The dark area gradually expanded and changed to a pericentral dark ring in both eyes. He had suffered from aplastic anemia for 4 years and received one blood transfusion per week for 8 months when he presented. He had also received five infusions of 301 mg antithymocyte globulin 1 month before the onset of visual loss (Fig. 1) and oral deferasirox beginning 4 months earlier. Deferasirox was discontinued after 1 month due to renal impairment and changed to deferoxamine infusion 1 month prior to visual loss. Past medical history included appendectomy (21 y), encephalitis (42 y), bilateral cataract surgery with pseudophakia (51 y) and curative treatment of prostate cancer (69 y). Best-corrected Snellen visual acuity (BCVA) was 0.6 in the right eye and 0.9 in the left eye, a serious detachment of the macula was found in both eyes and applanation tonometry was normal. Visual acuity deteriorated to 0.3 in both eyes 3 months later. A presumptive diagnosis of deferoxamine retinopathy prompted a switch to oral deferiprone, but visual acuity decreased to worse than 0.1 in both eyes over the following year. From half a year before presentation to half a year after presentation, plasma ferritin—a surrogate measure of iron stores—had ranged from 2000 to 7230 ng/mL (SI: 2000 to 7230 μg/L), reference range 15–320 ng/mL, with prominent peaks immediately before and after the onset of visual loss (Fig. 1). Patchy visual field

![Timeline chart for patient 1 and 2 with relevant blood tests and drug exposure.](image-url)
sensitivity loss (Fig. 2) was seen corresponding to hyper-
and hypofluorescent degeneration of the outer retina in
both maculae (Fig. 3) and severely reduced cone photo-
receptor density out 14 degrees from the foveola (Fig. 4).
There were no other signs of hemosiderosis.

**Patient 2**
A 70-year-old male erythropoiesis-deficient anemia
patient with floaters, flashes and poor color vision
was seen with BCVA 0.9 in the right eye and 1.0 in
the left eye. He had previously been diagnosed with

---

**Fig. 2** Automated perimetry examination of patient 1 and 2. Legend: Automated perimetry, 30-2, (Octopus 900, Haag-Streit, Switzerland) in two patients, patient 1 above at presentation and patient 2 below at 2 years after presentation. MS, mean sensitivity; MD, mean defect; and sLV, square root of loss variance.
type 2 diabetes mellitus (57 y), hypertension (57 y), diabetic nephropathy (68 y) and myelodysplastic syndrome with ring sideroblasts (65 y). Blood transfusions had been administered from the past 2 years prior and was continued after the onset of visual symptoms. Deferiprone, administered until 8 months earlier, had been switched to deferoxamine due to renal impairment (Fig. 1). A tentative diagnosis of vitreous degeneration was made, but 6 months later BCVA had dropped to 0.2 in both eyes. The suspicion that deferoxamine was the cause prompted discontinuation of this drug without chelator substitution. One year later BCVA had increased to 0.8 in the right eye and 0.4 in the left eye. It then fell to 0.4 in both eyes when seen 55 months after presentation, when geographic atrophy was seen in the left macula. Over the 6 years up to his most recent visit, plasma ferritin had ranged from 1500 to 10,030 ng/mL, with a peak near the onset of visual loss (Fig. 1). Visual field sensitivity was moderately diffusely reduced (Fig. 2) and both maculae showed granular hyper- and hypoauteofluorescence with corresponding photoreceptor and pigment epithelium atrophy (Figs. 3 and 4).

**Discussion and conclusions**

The outer retinal degeneration seen in our two patients fits the description of what is called deferoxamine retinopathy. It is remarkable, however, that neither case showed a clear temporal association between iron chelator exposure, disease duration or disease severity, and retinal degeneration. Remarkably, the onset of subjective visual loss occurred on the chronically rising slopes of plasma ferritin concentration curves that had exceeded the recommended maximum of 1000 ng/mL for years [13]. While this maximum has been set to safeguard the heart, there is insufficient data to estimate the level of ferritin that is safe for the retina. We did not observe any uniform pattern of changes in retinal function or structure and fluctuations in hemoglobin or c-reactive protein.

Competing with the notion that deferoxamine in itself should be retinotoxic [4, 14], there is evidence that iron overload can induce outer retinal degeneration by promoting the production of reactive oxygen species and an inherent increase in oxidative stress [12, 15]. Independent of the blood-retina barrier, human RPE cells have an abundance of transferrin receptors which permit
endocytosis-mediated iron uptake from the choroid [11]. Of particular note, our patients’ ocular characteristics are comparable those seen in hemochromatosis [16], in experimental intraocular iron toxicity [17, 18] and in intraocular ferrous foreign body retention, where the functional deficit is partially reversible [19], as was the visual loss in our patient 2.

The mechanism or etiology of a possible deferoxamine-induced toxicity is not understood; however, it is plausible that deferoxamine affects iron mobilization locally in the retina and thereby causes atrophy. Furthermore, clinical cases of presumed deferoxamine retinopathy have all occurred in patients with iron overload during some period of their disease [3], and rabbits with intraocular iron foreign bodies are protected from retinal degeneration by deferoxamine [20]. Deferiprone, an oral iron chelator, was shown to protect against retinal degeneration induced by systemic iron overload in mice [21, 22]. While deferoxamine can depress the electroretinogram, the effect is transient and was observed in patients with concurrent hemosiderosis [3].

Preclinical data from animal studies shows that iron overload can induce retinal damage [17, 23–25]. In addition, iron overload can also accelerate cell death in rats exposed to partial nerve head crush [26]. Knock-out of TIM2, the receptor for H-ferritin in Müller cells of the mouse retina, has led to iron overload and consequently production of reactive oxygen species and subsequent retinal degeneration [27]. Salvianic acid A, an extract from Chinese herbs, and Puerarin are agents used in alternative medicine that have been shown to ameliorate iron overload-induced toxicity in mice [28, 29]. The positive actions of these two drugs are believed to be through regulation of iron-handling proteins that possibly aid in iron chelation and attenuation of oxidative stress. These two drugs have not been tested in humans with hemosiderosis.

Ferroptosis, a recently described cell death mechanism that depends on an abundant concentration of iron [30], may theoretically be involved in retinal damage by promoting retinal cell death in hemosiderosis. Thus, a study has found evidence that ferroptosis contributed to
cell death in cultured human RPE cells exposed to iron overload, and that deferoxamine attenuated the rate of cell death [31].

Only a speculative case association with retinal degeneration has been reported for deferasirox and none for deferriprone, which are two alternative clinical iron chelating drugs [32]. Thus, the analysis of clinical cases may potentially be confounded by interaction between a reversible functional effect of deferoxamine and a more permanent effect of iron on the retina [3]. Notably, most clinical reports linking deferoxamine with retinal degeneration have not accounted for ferritin levels prior to, during or after vision loss. We therefore suspect that ferritin spikes or burst of cytokine release from disintegrating T-cells, as seen during antithymocyte therapy [33], may promote retinal degeneration, as may the natural accumulation of iron in the retina with aging [34]. Whether antithymocyte therapy or other unknown dysfunction in iron metabolism caused the retinal damage in our patient no. 1 to become irreversible can only be hypothesized.

Our two cases expand OCT-based demonstrations of attenuation and irregularity of the photoreceptor and RPE layers in the macula [5, 14]. Cone photoreceptor counts in affected areas were about half of what is normal, with considerable focal variations confined to the area within the temporal vascular arcades.

The complexity of the typical clinical course in anemia limits the retrospective analysis of causality in retinopathy cases, of whom the ones with the highest iron load are the ones who received the most intensive chelation therapy. Although our two cases were highly valuable in understanding the complexity of chronic anemia and retinopathy, we cannot generalize or establish cause-effect relationships based on our findings.

In conclusion, retinal injury in iron-overload anemia should not unreservedly be attributed to iron chelation therapy. Insufficient iron chelation should be considered as an alternative etiology. Proactive eye examination, meticulous clinical documentation and awareness of the guideline upper plasma ferritin level of 1000 ng/mL may help enable rational analysis of cases and reduction of the incidence of retinal degeneration in chronic anemia patients.

Abbreviations
BCVA: Best-corrected visual acuity; RPE: Retinal pigment epithelium

Acknowledgements
Not applicable.

Authors’ contributions
Concept and design: ML, CEH and MB. Acquisition, analysis or interpretation of data: All authors. Drafting of the manuscript: MB, CEH and ML. Critical revision of the manuscript for important intellectual content: TI, EL and BKM. Final approval of the manuscript: All authors.

Funding
The study was supported by the European Union under H2020-EU.2.1.1. - ID 780089 (MERLIN); Rigshospitalens (grant E-23334-02); P. Carl Petersens Fond (grant 19102); Aase og Ejnar Danielsens Fond (grant 18-10-0698); Helsefonden (grant 19-B-0063); Beckett Fondsen (grant 19-2-3490); and Einar Willum-sens Mindelag (grant 500028). None of the above-mentioned sources has had any role in the design, analysis or interpretation of data and in writing the manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
Ethics approval was not necessary for this case report.

Consent for publication
Both study participants gave their oral and written informed consent for publication.

Competing interests
ML has consulted, spoken or been a trial investigator for Novartis, Chiesi, Allergan, Bayer, Alcon, AbbVie, Biogen, Novo Nordisk, Eli Lilly, Spark Therapeutics, Nightstar, Sanofi and Roche.

Author details
1Department of Ophthalmology, Rigs hospitalet, Copenhagen University Hospital, Glostrup, Denmark. 2Department of Clinical Medicine, Faculty of Healthy and Medical Science, University of Copenhagen, Copenhagen, Denmark. 3Department of Hematology, Rigs hospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 4Department of Hematology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.

Received: 1 February 2021 Accepted: 29 June 2021
Published online: 13 July 2021

References
1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–93. https://doi.org/10.1038/sj.ha.4600907.
2. Viola F, Bargetselli G, Dell’Arti L, et al. Multimodal imaging in deferoxamine retinopathy. Retina. 2014;34(7):128–38. https://doi.org/10.1097/IAE.0000000000000073.
3. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huhrs H. Ocular toxicity of high-dose intravenous deferoxamine. Lancet. 1983; 2(8343):181–4. https://doi.org/10.1016/s0140-6736(83)90170-8.
4. D Nicola M, Bargetselli G, Dell’Arti L, Ratiglia R, Viola F. Functional and structural abnormalities in Deferoxamine retinopathy: a review of the literature. Biomed Res Int. 2015;2015:249617–2. https://doi.org/10.1155/2015/249617.
5. Van Boll L, Alami A, Benghiat FS, Rasquin F. Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases. Retinal Cases Brief Reports. 2014;8(2):97–102. https://doi.org/10.1097/CRB.000000000000013.
6. Gelman R, Kiss S, Tsang SH. Multimodal imaging in a case of deferoxamine-induced maculopathy. Retin Cases Brief Rep. 2014;8(4):306–9. https://doi.org/10.1097/CRB.000000000000055.
7. Georgakopoulou CD, Taspardoni F, Kostopoulou EV, Makri OE. Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature. BMC Ophthalmol. 2018;18(1):246. https://doi.org/10.1186/s12886-018-0911-2.
8. Nuzzi R, Geronazzo G, Tridico F, Nuzzi A, Caselgrandi P, Piga AG. Long-term effects of iron chelating agents on ocular function in patients with thalassemia major. Clin Ophthalmol. 2021;15:2099–109. https://doi.org/10.2147/OPTH.S300974.
9. Bhoiwala DL, Dunaief JL. Retinal abnormalities in β-thalassemia major. Surv Ophthalmol. 2016;61(1):33–50. https://doi.org/10.1016/j.survophthal.2015.08.005.
10. Kamińska A, Romano GL, Rejdkik R, et al. Influence of Trace Elements on Neurodegenerative Diseases of The Eye-The Glaucoma Model. Int J Mol Sci. 2021;22(9). https://doi.org/10.3390/ijms22094323.

11. Hunt RC, Dewey A, Davis AA. Transferin receptors on the surfaces of retinal pigment epithelial cells are associated with the cytoskeleton. J Cell Sci. 1985;92(Pt 4):655–66. https://doi.org/10.1242/jcs.92.4.655.

12. He X, Hahn P, Iacovelli J, Wong R, King C, Bhistukil R, et al. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res. 2007;26(6):649–73. https://doi.org/10.1016/j.preteyeres.2007.07.004.

13. Cappellini MD CA, Elefteriou A, et al. Guidelines for the clinical Management of Thalassemia. 2nd revised edition. Thalassemia International Federation, 2006.

14. Wu CH, Yang CP, Lai CC, Wu WC, Chen YH. Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. BMC Ophthalmol. 2014;14:88. https://doi.org/10.1186/1471-2415-14-88, 1.

15. Gnana-Prakasam JP, Martin PM, Smith SB, Ganapathy V. Expression and function of iron regulatory proteins in retina. JUBMB Life. 2010;62(5):363–70. https://doi.org/10.1002/jub.526.

16. Zerbib J, Pierre-Kahn V, Sikorav A, Oubraham H, Sayag D, Lobstein F, et al. Unusual retinopathy associated with hemochromatosis. Retin Cases Brief Rep. 2015;9(2):190–4. https://doi.org/10.1097/IOB.0000000000000135.

17. Masculi L, Anderson DR, Charles S. Experimental ocular siderosis in the squirrel monkey. Am J Ophthalmol. 1972;74(4):638–61. https://doi.org/10.1016/0002-9394(72)90826-4.

18. Decleercq SS, Meredith PC, Rosenthal AR. Experimental siderosis in the rabbit: correlation between electroretinography and histopathology. Arch Ophthalmol. 1977;95(6):1051–2. https://doi.org/10.1001/archoph.1977.01450060138014.

19. Kannan NB, Adenuga OO, Rajan RP, Ramasamy K. Management of Ocular Siderosis: visual outcome and Electroretinographic changes. J Ophthalmol. 2016;2016:7272465. https://doi.org/10.1155/2016/7272465.

20. Decleercq SS. Desferoxamine in ocular siderosis: a long-term electrophysiological evaluation. Br J Ophthalmol. 1980;64(8):626–9. https://doi.org/10.1136/bjo.64.8.626.

21. Hadziahmetovic M, Song Y, Wolkow N, Iacovelli J, Grieo S, Lee J, et al. The oral iron chelator deferriprone protects against iron overload-induced retinal degeneration. Invest Ophthalmol Vis Sci. 2011;52(2):959–68. https://doi.org/10.1167/iovs.10-6207.

22. Song D, Zhao L, Li Y, Hadziahmetovic M, Song Y, Connelly J, et al. The oral iron chelator deferriprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci. 2014;55(7):4525–32. https://doi.org/10.1167/iovs.14-14568.

23. Hahn P, Qian Y, Dentchev T, Chen L, Beard J, Harris ZL, et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci U S A. 2004;101(38):13850–4. https://doi.org/10.1073/pnas.0405146101.

24. Chaudhary K, Promisste W, Ananth S, Veeranan-Karmegam R, Tawfik A, Arjunan P, et al. Iron overload accelerates the progression of diabetic retinopathy in association with increased retinal renin expression. Sci Rep. 2018;8(1):3025. https://doi.org/10.1038/s41598-018-21276-2.

25. Zerdoun S, Fiedorowicz M, Redikik R, Choragiewicz TJ, Sulejczak D, Stopa P, et al. Influence of Trace Elements on Neurodegenerative Diseases of The Eye-The Glaucoma Model. Int J Mol Sci. 2021;22(9). https://doi.org/10.3390/ijms22094323.

26. Hunt RC, Dewey A, Davis AA. Transferin receptors on the surfaces of retinal pigment epithelial cells are associated with the cytoskeleton. J Cell Sci. 1985;92(Pt 4):655–66. https://doi.org/10.1242/jcs.92.4.655.

27. He X, Hahn P, Iacovelli J, Wong R, King C, Bhistukil R, et al. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res. 2007;26(6):649–73. https://doi.org/10.1016/j.preteyeres.2007.07.004.

28. Song Q, Zhao Y, Li Q, Han X, Duan J. Puerarin protects against iron overload-induced retinal injury through regulation of iron-handling proteins. Biomed Pharmacother. 2020;122:109690. https://doi.org/10.1016/j.biopha.2019.109690.

29. Li C, Cao F, Yin HJ, et al. Ferroptosis: past, present and future. Cell Death & Disease. 2020;11(2):68. https://doi.org/10.1038/s41419-020-2298-2.

30. Totsuka K, Ueta T, Uchida T, Roggia MF, Nakagawa S, Vavass DG, et al. Oxidative stress induces ferroptotic cell death in retinal pigment epithelial cells. Exp Eye Res. 2019;181:136–24. https://doi.org/10.1016/j.exer.2018.08.019.

31. Walia HS, Yan J. Reversible retinopathy associated with oral deferasirox therapy. BMJ Case Rep. 2013;2013:bcr2013009205. https://doi.org/10.1136/bmjcr-2013-009205.

32. Munch IC, Traustason S, Olgaard K, Larsen M. Acute macular neuroretinopathy in relation to anti-thymocyte globulin infusion. Acta Ophthalmol. 2012;90(4):e821–2. https://doi.org/10.1111/j.1755-378X.2011.02276.x.

33. Chen H, Lukas TJ, Du N, Suyeoka G, Neufeld AH. Dysfunction of the retinal pigment epithelium with age: increased iron decreases phagocytosis and lysosomal activity. Invest Ophthalmol Vis Sci. 2009;50(4):1895–902. https://doi.org/10.1167/iovs.08-2850.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.